For older adults (55+): Lower starting doses of 100-200 mcg are often recommended, with gradual increases as tolerated
IGF-1 LR3 and Semaglutide Together Goal: Body recomposition with a focus on fat loss
However, several key considerations must inform their clinical application
GLP 1 receptor agonists and dual incretin therapies are delivering measurable, outcome driven results: 12% to 27% relative risk reduction in major adverse cardiovascular events across CVOTs 13% to 14% reduction in cardiovascular death in meta analyses 11% to 14% reduction in hospitalization for heart failure 24% relative risk reduction in kidney outcomes in the dedicated FLOW trial with semaglutide Up to 15.8% weight loss with semaglutide 2.4 mg 20.2% weight loss with tirzepatide 15 mg in head to head obesity trials 66% to 93% reduction in progression from prediabetes to type 2 diabetes This is no longer about glucose (or weight loss) alone
Most adults can benefit from supporting their antioxidant levels, especially as they get older or during times of high stress
But in patients with pre-existing inflammatory bowel disease, the inflammatory cascade in the colon may be sensitized or amplified by GLP-1 activation, potentially triggering flares or worsening existing inflammation
